Commenting on the results, Bhushan Akshikar, MD of GlaxoSmithKline Pharmaceuticals, highlighted the company’s strategic initiatives in strengthening its market presence and enhancing access to ...

GlaxoSmithKline Pharmaceuticals shares hit 20 per cent upper circuit in trade on BSE at Rs 2,421.3 per share. The buying on the counter came after the company posted its Q3 results. Around 9:52 AM, ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President. The Food ...

คนร้ายแสบ ลอบวางจยย.ติดคาร์บอมบ์ ข้างกำแพงรั้ว อส.แว้ง เจ็บ 13 วงจรปิดจับภาพ 2 คนร้าย เร่ง ...

Vivian Wan / Bloomberg via Getty Images GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. GSK's Beat-and-Raise ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results. When investing, your capital is at risk. The value of your ...

HL Building Blocks Build your own portfolio with HL's specially designed fund range Wealth Shortlist A selection of funds we've researched and chosen for their long-term potential ...

(Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion ...